Atomoxetine for treatment of marijuana dependence: a report on the efficacy and high incidence of gastrointestinal adverse events in a pilot study

Drug and Alcohol Dependence
Carlos F TiradoCharles P Obrien

Abstract

Marijuana users consistently demonstrate impairments in attention, executive function and response inhibition, which resemble deficits seen in attention deficit hyperactivity disorder (ADHD). We hypothesized that targeting the cognitive deficits associated with chronic marijuana use through ADHD medications may help identify a therapeutic agent for marijuana dependence. Thirteen subjects participated in an 11-week open label study to determine the feasibility, safety and tolerability of atomoxetine for individuals seeking treatment for marijuana dependence. The Time-Line Follow-Back measured marijuana use 90 days prior to study entry (p-TLFB) and weekly during the study (s-TLFB) along with weekly qualitative urine drug screen (UDS). For the eight subjects who completed the trial, the TLFB data showed a trend toward reduction in use with an increase in percent days abstinent (p=0.06). Analysis of weekly UDSs did not confirm the TLFB trend with 94% of all possible UDSs positive for THC through out the study. Marijuana dependent subjects taking atomoxetine experienced an inordinate number of gastrointestinal (GI) adverse events. Overall, 10 of 13 subjects (77%) experienced a mild to moderate GI adverse event defined as nausea, vom...Continue Reading

Associated Clinical Trials

References

Feb 24, 2001·Trends in Pharmacological Sciences·A A IzzoF Capasso
Jun 13, 2001·Psychopharmacology·M HaneyM W Fischman
Mar 7, 2002·JAMA : the Journal of the American Medical Association·Nadia SolowijUNKNOWN Marijuana Treatment Project Research Group
Oct 16, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Margaret HaneyRichard W Foltin
Feb 10, 2004·The American Journal on Addictions·Frances Rudnick LevinSuzanne K Vosburg
Oct 30, 2004·The American Journal of Psychiatry·Alan J BudneyRyan Vandrey
Feb 4, 2005·Journal of the American Academy of Child and Adolescent Psychiatry·Torkel KlingbergHelena Westerberg
Feb 17, 2006·Clinical Psychology Review·Amy L Krain, F Xavier Castellanos
Mar 31, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Johannes G RamaekersManfred R Moeller
Jun 14, 2006·Drug and Alcohol Dependence·Alan J BudneyBetsy Bahrenburg
Aug 24, 2006·Journal of the American Academy of Child and Adolescent Psychiatry·Christopher J KratochvilHimanshu Upadhyaya
Sep 13, 2006·The American Journal on Addictions·Aimee L McRaeRickey E Carter
Dec 8, 2006·The American Journal of Psychiatry·Timothy E Wilens

❮ Previous
Next ❯

Citations

Apr 16, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Toru KobayashiKazutaka Ikeda
Jan 1, 2011·ILAR Journal·Divya RameshAron H Lichtman
Jun 26, 2009·CNS Drugs·Ryan Vandrey, Margaret Haney
Oct 7, 2014·Drug and Alcohol Dependence·Meredith A KellyFrances R Levin
Apr 16, 2009·International Review of Psychiatry·Jan Copeland, Wendy Swift
Mar 19, 2008·Expert Review of Neurotherapeutics·Amine BenyaminaMichael Lukasiewcz
May 30, 2012·The Psychiatric Clinics of North America·Itai Danovitch, David A Gorelick
Nov 18, 2009·Pharmacology & Therapeutics·Bianca Jupp, Andrew J Lawrence
Aug 25, 2009·Drug and Alcohol Dependence·Aimee L McRae-ClarkKathleen T Brady
Oct 21, 2010·The American Journal on Addictions·Aimee L McRae-ClarkKathleen T Brady
Dec 12, 2012·British Journal of Clinical Pharmacology·José Pérez de los CobosJoan Trujols
Jan 21, 2014·Drug and Alcohol Dependence·João Mauricio Castaldelli-MaiaSilvia S Martins
Sep 7, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Christina A Brezing, Frances R Levin
Dec 18, 2014·The Cochrane Database of Systematic Reviews·Kushani MarshallBernard Le Foll
Oct 24, 2017·Expert Opinion on Emerging Drugs·Eduardo R Butelman, Mary Jeanne Kreek
May 10, 2017·Annals of the New York Academy of Sciences·Katherine M NautiyalCarlos Blanco
Apr 15, 2009·Current Opinion in Psychiatry

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.